Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Nearly 40 million yuan invested in R&D; Health Yuan's monoclonal antibody injection approved for clinical trial

Time Posted:2020-02-19 20:07

On February 19, Jiankangyuan issued an announcement stating that its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (Lizhu Monoclonal Antibody), and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd. (Xinkanghe Bio) have received approval from the National Medical Products Administration for their jointly submitted clinical trial application for "Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection."

Announcement on the Acceptance of Clinical Trial Application for Drugs by Joincare Pharmaceutical Group Industry Co., Ltd.

Time Posted:2020-02-18 20:14

The board of directors and all directors of this company guarantee that the content of this announcement contains no false records, misleading statements, or major omissions, and assume individual and joint and several liability for the authenticity, accuracy, and completeness of its content.

Joincare Pharmaceutical Group Industry Co., Ltd. Announcement on Obtaining Drug Acceptance Notice

Time Posted:2020-02-18 20:10

Announcement on Obtaining Drug Acceptance Notification Letter The board of directors and all directors of this company guarantee that the content of this announcement does not contain any false records, misleading statements, or major omissions, and assume individual and joint and several liability for the authenticity, accuracy, and completeness of its content.

Healthy Yuan: Plans to repurchase company shares with its own funds ranging from 150 million to 300 million.

Time Posted:2020-02-10 20:16

Lanfu Finance reported on February 10 that Healthy Yuan announced that the company intends to repurchase its shares through centralized bidding using its own funds; the total amount of funds for share repurchase: no less than RMB 150 million (inclusive) and no more than RMB 300 million (inclusive); repurchase price: no more than RMB 15/share (inclusive), repurchase period: within 12 months from the date the company's board of directors approves the share repurchase plan. Repurchase purpose: The repurchased shares will be used for employee stock ownership plans and equity incentives, of which 40% of the repurchased shares will be used for employee stock ownership plans, and 60% will be used for equity incentive plans.

Lizhu Reagent and the Wuhan Institute of Virology, Chinese Academy of Sciences, have successfully developed a rapid colloidal gold antibody detection reagent that produces results within 15 minutes.

Time Posted:2020-02-02 20:27

To accelerate the detection of the novel coronavirus and effectively control the further spread of the epidemic, after Lizhu Reagent jointly developed the Novel Coronavirus IgG/IgM Serological Diagnostic Kit (ELISA) with the Wuhan Institute of Virology, Chinese Academy of Sciences, and independently developed the Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (PCR-fluorescence probe method)/(PCR fluorescence method), today it has successfully jointly developed with the Wuhan Institute of Virology, Chinese Academy of Sciences, the Novel Coronavirus IgG/IgM Detection Kit (colloidal gold method), which can produce test results within 15 minutes, racing against the virus to win precious time, and adding another weapon to fight the epidemic. Single-person detection, manual and automated operation can assist primary-level medical institutions in early screening and diagnosis. As epidemic prevention and control enters a critical stage, primary-level medical institutions will become the main battlefield for the discovery and isolation of the epidemic. Currently, primary-level medical institutions lack large-scale testing equipment, making large-scale testing and screening extremely difficult. In the face of the pressure of epidemic prevention and control, the primary level urgently needs the support of a small, lightweight, and rapid testing system. In response to this situation, Lizhu Reagent quickly launched research and development and transformation, and completed the development of the Novel Coronavirus IgG/IgM Rapid Detection Kit (colloidal gold method). Novel Coronavirus IgG/IgM Rapid Detection Kit (colloidal gold method) 1) Sample types can be whole blood/serum/plasma; 2) Manual and automated operation is possible. Applied to the GS1201 rapid detection platform for rapid detection of pathogens in outpatient clinics. Currently, Lizhu Reagent's Novel Coronavirus IgG/IgM Rapid Detection Kit (colloidal gold method) has applied for entry into the fast-track approval process and will soon be launched for use on the front line of epidemic prevention and control, helping to solve the early screening and diagnosis of suspected cases at the primary level and assisting the primary-level battlefield in winning the battle against epidemic prevention and control.

Public Notice on the Completion Acceptance of Environmental Protection for the Upgrading and Transformation Project of 50,000-ton Annual Output of Organic Fertilizer Raw Material Sludge Disposal of Jiaozuo Jiankangyuan Bio-products Co., Ltd.

Time Posted:2020-01-04 20:39

In accordance with the requirements of the "State Council Decision on Amending the Regulations on Environmental Protection Management of Construction Projects" (State Council Order No. 682) and the "Interim Measures for the Acceptance of Environmental Protection upon Completion of Construction Projects" (Guo Huan Gui Huan Ping [2017] No. 4), the main contents of the "Completion Acceptance Monitoring Report on Environmental Protection of the 50,000-ton Annual Output of Organic Fertilizer Raw Material Sludge Disposal and Upgrading and Transformation Project of Jiaozuo Jiankangyuan Bioproducts Co., Ltd." and the acceptance opinions are hereby publicized.

Ten famous companies are on the list! Health Yuan won the "2019 Guangdong-Hong Kong-Macao Greater Bay Area Listed Company of the Year"

Time Posted:2019-12-29 20:42

The 2019 Guangdong-Hong Kong-Macao Greater Bay Area Listed Companies Annual Conference and Corporate Social Responsibility Summit, jointly hosted by Xinhua Net, China Securities Journal, Shanghai Securities News, and the Xinhua News Agency National Brand Project Office, was grandly held in Shenzhen on December 26. Themed "Co-creation, Sharing, Responsibility," the conference invited numerous well-known listed company chairmen, economists, financial institution heads, and think tank experts to discuss the opportunities and challenges in the capital market and talk about the social responsibility of listed companies.

Supporting the development of Guangdong's pharmaceutical industry, Health Yuan receives multiple honors from the Review and Evaluation Association

Time Posted:2019-12-25 20:46

On December 18, 2019, the "Seventh Anniversary and the Second Meeting of the Second Member Representative Conference," hosted by the Guangdong Food and Drug Administration Evaluation and Certification Technology Association (GD-FDTAEC), was grandly held at the Guangzhou Central Crowne Plaza Hotel. Relevant leaders from the Guangdong Provincial Drug Supervision and Administration Bureau, along with over 400 renowned experts and enterprise representatives from the pharmaceutical industry in the province, attended the conference. Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan Pharmaceutical Group") attended the conference as an outstanding enterprise representative. Yu Zhanfeng, deputy head of the Zhuhai Greater Health Production Base project team, and the quality control personnel from the Nanshan Production Center of the Group were present.

< 1...424344...55 >